Tom 14, Nr 4 (2018)
Artykuł przeglądowy sponsorowany
Opublikowany online: 2019-02-26
Wyświetlenia strony
2001
Wyświetlenia/pobrania artykułu
8317
Patogeneza udaru niedokrwiennego mózgu — możliwości neuroprotekcji i stymulowania plastyczności mózgu
Pol. Przegl. Neurol 2018;14(4):230-239.
Streszczenie
Choroby naczyniowe mózgu są jedną z najczęstszych przyczyn zgonu i kalectwa, a liczba zachorowań w wielu krajach świata stale wzrasta. W ostatnich latach dokonał się duży postęp wiedzy o podstawowych mechanizmach molekularnych odpowiedzialnych za procesy neurodegeneracyjne. Stało się to możliwe dzięki wprowadzeniu zwierzęcych modeli doświadczalnych oraz zastosowaniu nowoczesnych metod obrazowania. W niniejszym artykule przestawiono kaskadę zmian patofizjologicznych w przebiegu niedokrwienia mózgu oraz najważniejsze przykłady terapii ukierunkowanej na neuroprotekcję i stymulowanie neuroplastyczności ośrodkowego układu nerwowego (OUN).
Na podstawie dotychczasowych badań należy stwierdzić, że mimo dotychczasowych niepowodzeń terapii neuroprotekcyjnej w chorobach OUN strategia stymulowania neuroregeneracji/neuroplastyczności będzie zajmować coraz ważniejsze miejsce we współczesnej neurologii.
Słowa kluczowe: udar niedokrwienny mózgupatofizjologianeuroprotekcjaneuroplastyczność
Referencje
- Thrift AG, Thayabaranathan T, Howard G, et al. Global stroke statistics. Int J Stroke. 2017; 12(1): 13–32.
- Hankey GJ. Stroke. The Lancet. 2017; 389(10069): 641–654.
- Pulsinelli WA, Brierley JB, Plum F. Temporal profile of neuronal damage in a model of transient forebrain ischemia. Ann Neurol. 1982; 11(5): 491–498.
- Pulsinelli W. Patophysiology of acute ischemic stroke. Lancet. 1992; 339: 533–536.
- Ginsberg MD, Palesch YY, Hill MD, et al. ALIAS and Neurological Emergencies Treatment Trials (NETT) Investigators. High-dose albumin treatment for acute ischaemic stroke (ALIAS) Part 2: a randomised, double-blind, phase 3, placebo-controlled trial. Lancet Neurol. 2013; 12(11): 1049–1058.
- Kane I, Sandercock P, Wardlaw J. Magnetic resonance perfusion diffusion mismatch and thrombolysis in acute ischaemic stroke: a systematic review of the evidence to date. J Neurol Neurosurg Psychiatry. 2007; 78(5): 485–491.
- Mair G, Wardlaw JM. Imaging of acute stroke prior to treatment: current practice and evolving techniques. Br J Radiol. 2014; 87(1040): 20140216.
- Naritomi H, Sasaki M, Kanashiro M, et al. Flow thresholds for cerebral energy disturbance and Na+ pump failure as studied by in vivo 31P and 23Na nuclear magnetic resonance spectroscopy. J Cereb Blood Flow Metab. 1988; 8(1): 16–23.
- Erecińska M, Nelson D, Wilson DF, et al. Neurotransmitter amino acids in the CNS. I. Regional changes in amino acid levels in rat brain during ischemia and reperfusion. Brain Res. 1984; 304(1): 9–22.
- Attia MS, Lass E, Loch Macdonald R. Nitric oxide synthases: three pieces to the puzzle? Acta Neurochir Suppl. 2015; 120: 131–135.
- Franklin TB, Krueger-Naug AM, Clarke DB, et al. The role of heat shock proteins Hsp70 and Hsp27 in cellular protection of the central nervous system. Int J Hyperthermia. 2005; 21(5): 379–392.
- Sakai S, Shichita T. Inflammation and neural repair after ischemic brain injury. Neurochem Int. 2018 [Epub ahead of print].
- Ao LY, Yan YY, Zhou L, et al. Immune cells after ischemic stroke onset: roles, migration, and target intervention. J Mol Neurosci. 2018; 66(3): 342–355.
- Ferrer. : 2006.
- Sekerdag E, Solaroglu I, Gursoy-Ozdemir Y. Cell death mechanisms in stroke and novel molecular and cellular treatment options. Curr Neuropharmacol. 2018; 16(9): 1396–1415.
- Choi JH, Pile-Spellman J. Reperfusion changes after stroke and practical approaches for neuroprotection. Neuroimaging Clin N Am. 2018; 28(4): 663–682.
- Shi L, Rocha M, Leak RK, et al. A new era for stroke therapy: integrating neurovascular protection with optimal reperfusion. J Cereb Blood Flow Metab. 2018; 38(12): 2073–2091.
- Ginsberg MD. Expanding the concept of neuroprotection for acute ischemic stroke: the pivotal roles of reperfusion and the collateral circulation. Prog Neurobiol. 2016; 145-146: 46–77.
- Ginsberg MD. Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology. 2008; 55(3): 363–389.
- Spilovska K, Zemek F, Korabecny J, et al. Adamantane — a lead structure for drugs in clinical practice. Curr Med Chem. 2016; 23(29): 3245–3266.
- Giacino JT, Whyte J, Bagiella E, et al. Placebo-controlled trial of amantadine for severe traumatic brain injury. N Engl J Med. 2012; 366(9): 819–826.
- Hinchcliffe M, Smith A. Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis. Degener Neurol Neuromuscul Dis. 2017; 7: 61–70.
- Kobayashi T, Mori Y. Ca2+ channel antagonists and neuroprotection from cerebral ischemia. Eur J Pharmacol. 1998; 363(1): 1–15.
- Chamorro Á, Dirnagl U, Urra X, et al. Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation. Lancet Neurol. 2016; 15(8): 869–881.
- Chan SuJ, Love C, Spector M, et al. Endogenous regeneration: Engineering growth factors for stroke. Neurochem Int. 2017; 107: 57–65.
- Wiszniewska M, Członkowska A. Rola cerebrolizyny w neuroprotekcji i neuroregeneracji — przegląd piśmiennictwa. Pol Przeg Neurol. 2014; 10(3): 114–122.
- Muresanu DF, Heiss WD, Hoemberg V, et al. Cerebrolysin and recovery after stroke (CARS): a randomized, placebo-controlled, double-blind, multicenter trial. Stroke. 2016; 47(1): 151–159.
- Saver JL. Citicoline: update on a promising and widely available agent for neuroprotection and neurorepair. Rev Neurol Dis. 2008; 5(4): 167–177.
- Boudouresques AB, Michel B. Therapeutic conduct in light of cerebral vascular accident and the use of CDP-choline. Presented at the International Symposium: Brain suffering and precursors of phospholipids. Paris, January 18, 1980.
- Goyas JY, Bastard J, Missoum A. Results after 90 days of stroke treatment with CDP cholinę concerning a double blind trial (in French). Presented at: International Symposium: brain suffering and precursors of phospholipids. Paris, January 18, 1980: 123–128.
- Corso EA, Arena M, Ventimiglia A, et al. [CDP choline in cerebral vasculopathy: clinical evaluation and instrumental semeiology]. Clin Ter. 1982; 102(4): 379–386.
- Tazaki Y, Sakai F, Otomo E, et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke. 1988; 19(2): 211–216.
- Clark WM, Warach SJ, Pettigrew LC, et al. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Citicoline Stroke Study Group. Neurology. 1997; 49(3): 671–678.
- Clark WM, Williams BJ, Selzer KA, et al. A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke. 1999; 30(12): 2592–2597.
- Warach S, Pettigrew LC, Dashe JF, et al. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators. Ann Neurol. 2000; 48(5): 713–722.
- Clark WM, Wechsler LR, Sabounjian LA, et al. Citicoline Stroke Study Group. A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology. 2001; 57(9): 1595–1602.
- Lin WX. The theraputic effect of edavarone for acute cerebral infarction. Chin J Integ Med. Cardio/Cerebrovasc Dis (Chinese. 2007; 5: 205–207.
- Alvairez E, Gonzalez M. Effectiveness and tolerability of citicoline in acute ischemic stroke, randomized, double blind study compared with placebo. Archivos Venezolanos de Farmacologia y Terapeutica. 2007; 26: 127–30.
- Cho HJ, Kim YJ. Efficacy and safety of oral citicoline in acute ischemic stroke: drug surveillance study in 4,191 cases. Methods Find Exp Clin Pharmacol. 2009; 31(3): 171–176.
- Leon-Jimenez E, Chiquete E, Cantu C, et al. Citicoline for acute ischemic stroke in Mexican hospitals: a retrospective post-marketing analysis. Methods Find Exp Clin Pharmacol. 2010; 32(5): 325–330.
- Mitta M, Goel D, Bansal KK, et al. Edaravone — citicoline comparative study in acute ischemic stroke (ECCS-AIS). J Assoc Physicians India. 2012; 60: 36–38.
- Dávalos A, Alvarez-Sabín J, Castillo J, et al. International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet. 2012; 380(9839): 349–357.
- Grewal N, Sharma G, Mohan G, et al. To study efficacy and safety of citicoline in acute ischemic stroke. Int J Basic Clin Pharmacol. 2012; 1(1): 72–76.
- Secades JJ, Alvarez-Sabín J, Rubio F, et al. Trial Investigators. Citicoline in intracerebral haemorrhage: a double-blind, randomized, placebo-controlled, multi-centre pilot study. Cerebrovasc Dis. 2006; 21(5-6): 380–385.
- Chua R. Role of intravenous citicole for supratentorial hemorrhage. Cerebrovasc Dis. 2007; 23(Suppl 2): 73.
- Corso EA, Arena M, Ventimiglia A, et al. [CDP choline in cerebral vasculopathy: clinical evaluation and instrumental semeiology]. Clin Ter. 1982; 102(4): 379–386.
- Secades JJ, Alvarez-Sabín J, Castillo J, et al. Citicoline for acute ischemic stroke: a systematic review and formal meta-analysis of randomized, double-blind, and placebo-controlled trials. J Stroke Cerebrovasc Dis. 2016; 25(8): 1984–1996.
- Hazama T, Hasegawa T, Ueda S, et al. Evaluation of the effect of CDP-choline on poststroke hemiplegia employing a double-blind controlled trial. Assessed by a new rating scale for recovery in hemiplegia. Int J Neurosci. 1980; 11(3): 211–225.
- Iranmanesh F, Vakilian A. Efficiency of citicoline in increasing muscular strength of patients with nontraumatic cerebral hemorrhage: a double-blind randomized clinical trial. J Stroke Cerebrovasc Dis. 2008; 17(3): 153–155.
- Dávalos A, Castillo J, Alvarez-Sabín J, et al. Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke. 2002; 33(12): 2850–2857.
- Shi PY, Zhou XC, Yin XX, et al. Early application of citicoline in the treatment of acute stroke: a meta-analysis of randomized controlled trials. J Huazhong Univ Sci Technolog Med Sci. 2016; 36(2): 270–277.
- Agarwal S, Patel BM. Is aura around citicoline fading? A systemic review. Indian J Pharmacol. 2017; 49(1): 4–9.
- Alvarez-Sabín J, Ortega G, Jacas C, et al. Long-term treatment with citicoline may improve poststroke vascular cognitive impairment. Cerebrovasc Dis. 2013; 35(2): 146–154.
- Alvarez-Sabín J, Santamarina E, Maisterra O, et al. Long-term treatment with citicoline prevents cognitive decline and predicts a better quality of life after a first ischemic stroke. Int J Mol Sci. 2016; 17(3): 390.
- Knecht T, Story J, Liu J, et al. Adjunctive therapy approaches for ischemic stroke: innovations to expand time window of treatment. Int J Mol Sci. 2017; 18(12): 2756.
